- Home
- AMLX vs VSTM Comparison
AMLX vs VSTM Comparison
Compare AMLX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- VSTM
- Stock Information
- Founded
- AMLX 2014
- VSTM 2010
- Country
- AMLX United States
- VSTM United States
- Employees
- AMLX N/A
- VSTM N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- VSTM Health Care
- Exchange
- AMLX Nasdaq
- VSTM Nasdaq
- Market Cap
- AMLX 459.1M
- VSTM 425.9M
- IPO Year
- AMLX 2022
- VSTM 2012
- Fundamental
- Price
- AMLX $7.68
- VSTM $4.69
- Analyst Decision
- AMLX Strong Buy
- VSTM Strong Buy
- Analyst Count
- AMLX 8
- VSTM 9
- Target Price
- AMLX $11.00
- VSTM $12.63
- AVG Volume (30 Days)
- AMLX 2.1M
- VSTM 2.5M
- Earning Date
- AMLX 08-07-2025
- VSTM 08-07-2025
- Dividend Yield
- AMLX N/A
- VSTM N/A
- EPS Growth
- AMLX N/A
- VSTM N/A
- EPS
- AMLX N/A
- VSTM N/A
- Revenue
- AMLX N/A
- VSTM $10,000,000.00
- Revenue This Year
- AMLX N/A
- VSTM $129.06
- Revenue Next Year
- AMLX N/A
- VSTM $306.32
- P/E Ratio
- AMLX N/A
- VSTM N/A
- Revenue Growth
- AMLX N/A
- VSTM N/A
- 52 Week Low
- AMLX $1.76
- VSTM $2.10
- 52 Week High
- AMLX $7.72
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- AMLX 75.73
- VSTM 39.03
- Support Level
- AMLX $5.97
- VSTM $4.60
- Resistance Level
- AMLX $6.86
- VSTM $4.90
- Average True Range (ATR)
- AMLX 0.54
- VSTM 0.32
- MACD
- AMLX 0.13
- VSTM 0.10
- Stochastic Oscillator
- AMLX 98.29
- VSTM 64.29
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.